RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update
RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced financial results and business highlights for the three months ended September 30, 2022
By RVL Pharmaceuticals plc
Published - Nov 10, 2022, 04:08 PM ET
Last Updated - Apr 24, 2024, 01:03 PM EDT
-- Third quarter 2022 UPNEEQ ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 --
-- Approximately 3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 2022, a 59% increase from the end of the second quarter 2022 --
-- Anticipates fourth quarter 2022 UPNEEQ net product sales to grow approximately 20% - 40% over the third quarter 2022, representing sales of approximately $12 - $14 million –
-- Plans to launch new eCommerce platform in first quarter 2023 --
